Search Results 331-340 of 16521 for Proliferation

  1. Publications - Min Shi, M.D., Ph.D. - Mayo Clinic

    ... proliferation: a diagnostic pitfall. Histopathology 2023 Dec; 83 (6):999-1002 Epub 2023 Sept 04. View PubMed; Yuan J, Liu H, Hu S, Miranda RN, Xu X, Bayerl MG ...

  2. Publications - Craig M. Horbinski, M.D. - Mayo Clinic

    Optimizing the use of Ki-67 proliferative index as a prognostic biomarker in meningiomas using digital analysis. J Neurosurg. 2024 Dec 1; 141 (6):1644-1654 ...

  3. Publications - Zhaohui Jin, M.D. - Mayo Clinic

    ... proliferation. J Biol Chem. 2004 Sep 17; 279 (38):40209-19 Epub 2004 June 21. View PubMed; Jin Z, Gao F, Flagg T, Deng X. Nicotine induces multi-site ...

  4. A Study Of Belantamab Mafodotin Administered In Combination With Lenalidomide And Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, And Dexamethasone (DRd) In Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible For Autologous Stem Cell Transplantation (TI-NDMM) - Mayo Clinic

    ... proliferative disorder, skin changes) or Primary Plasma Cell Leukemia (defined as circulating plasma cells \>5%). 2. Prior systemic therapy for multiple ...

  5. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) - Mayo Clinic

    Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically, one or more of the following:.

  6. A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients with Mayo Stage IIIa AL Amyloidosis

    ... proliferative disorder (eg, multiple myeloma and POEMS syndrome) specifically: i. Hypercalcemia: serum calcium \> 0.25 mmol/L (\> 1 mg/dL) higher than the ...

  7. Science Saturday: Regenerative medicine at Mayo ramps up

    “The iPSCs resemble almost exactly the embryonic stem cells, which means they have unlimited potential to proliferate, and also the potential to ...

  8. First-in-Human Study of FLX925 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia - Mayo Clinic

    For rapidly proliferative disease, use of hydroxyurea is allowed before and up to 7 days on therapy. Clinically significant toxic effects of any prior ...

  9. Non Clinical Trials - Mayo Clinic Research

    Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, ...

  10. Myocardial Ischemia and Transfusion - Mayo Clinic

    Inclusion Criteria: 18 years of age or older; Either ST segment elevation myocardial infarction or Non ST segment elevation myocardial infarction consistent ...